Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of PN for at least 3 months before screening.~* Inadequate response or intolerant to ongoing or prior PN therapy.~* ≥ 20 pruriginous lesions on ≥ 2 different body regions at screening and Day 1.~* Willingness to avoid pregnancy or fathering children~* Further inclusion criteria apply.~Exclusion Criteria:~* Have chronic pruritus due to a condition other than PN; have neuropathic and psychogenic pruritus such as but not limited to notalgia paresthetica, brachioradial pruritus, small fiber neuropathy, skin picking syndrome, or delusional parasitosis.~* Current use of a medication known to cause pruritus.~* Women who are pregnant (or who are considering pregnancy) or lactating.~* Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q-wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator.~* Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis.~* Participants known to be infected with HIV, Hepatitis B, or Hepatitis C.~* Laboratory values outside of the protocol-defined ranges.~* Further exclusion criteria apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- INCB054707 Dose A (Type: EXPERIMENTAL): Participants will receive INCB054707 Dose A for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).
- INCB054707 Dose B (Type: EXPERIMENTAL): Participants will receive INCB054707 Dose B for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).
- INCB054707 Dose C (Type: EXPERIMENTAL): Participants will receive INCB054707 Dose C for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).
- Placebo followed by INCB054707 Dose B or C (Type: PLACEBO_COMPARATOR): Participants will receive placebo for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).

Based on this trial design, predict the completion outcome and termination type (if applicable).